Bayer (FRA:BAYN)‘s stock had its “buy” rating reissued by analysts at Citigroup in a research note issued on Thursday.

Several other brokerages have also recently issued reports on BAYN. Barclays set a €105.00 ($125.00) price objective on shares of Bayer and gave the stock a “sell” rating in a research note on Monday, November 6th. Goldman Sachs Group set a €125.00 ($148.81) price objective on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday, November 7th. UBS set a €125.00 ($148.81) price objective on shares of Bayer and gave the stock a “buy” rating in a research note on Monday, November 6th. Berenberg Bank set a €124.00 ($147.62) price objective on shares of Bayer and gave the stock a “neutral” rating in a research note on Friday, November 3rd. Finally, Jefferies Group set a €137.00 ($163.10) price objective on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of €122.19 ($145.46).

Shares of Bayer (FRA:BAYN) traded down €0.90 ($1.07) on Thursday, hitting €103.95 ($123.75). 861,469 shares of the stock traded hands. Bayer has a 12 month low of €86.60 ($103.10) and a 12 month high of €123.82 ($147.40).

ILLEGAL ACTIVITY WARNING: “Bayer (BAYN) Given Buy Rating at Citigroup” was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/bayer-bayn-given-buy-rating-at-citigroup.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer AG and related companies with MarketBeat.com's FREE daily email newsletter.